Information Provided By: 
Fly News Breaks for May 1, 2019
ANTX
May 1, 2019 | 16:09 EDT
Oppenheimer analyst Kevin DeGeeter initiated Athenex with an Outperform and $20 price target based on expectations for positive Q3 Oraxol Phase 3 breast cancer data, survey results that indicate potential meaningful uptake of KX2-391 for the treatment of actinic keratosis, and the company's commercial channel for specialty oncology products. Further, the analyst expects partnering as an important catalyst over the next 12-24 months.
News For ANTX From the Last 2 Days
There are no results for your query ANTX
